Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026
Go back to Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 63.96 +2.16 (3.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.80 | 52 Week High | $0.52 | |||
| Open | $63.96 | 52 Week Low | $0.08 | |||
| Day High | $65.42 | P/E | N/A | |||
| Day Low | $60.73 | EPS | $-3.80 | |||
| Volume | 24,078,869 | |||||
